Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 11219487)

1.

Bodyweight gain with atypical antipsychotics. A comparative review.

Wetterling T.

Drug Saf. 2001 Jan;24(1):59-73. Review.

PMID:
11219487
2.

[Weight gain from atypical neuroleptics--an underreported adverse effect?].

Wetterling T.

Fortschr Neurol Psychiatr. 2000 Dec;68(12):546-56. Review. German.

PMID:
11200858
3.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
4.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
5.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;11:CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
6.

[Atypical antipsychotic drugs].

Kahn RS.

Ned Tijdschr Geneeskd. 2000 Aug 19;144(34):1627-30. Review. Dutch.

PMID:
10972052
7.

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.

Kapur S, Remington G.

Annu Rev Med. 2001;52:503-17. Review.

PMID:
11160792
8.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
9.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
10.
11.

Review of atypical antipsychotics and weight gain.

Sussman N.

J Clin Psychiatry. 2001;62 Suppl 23:5-12. Review.

PMID:
11603886
12.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
13.

Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.

Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.

Am J Psychiatry. 2004 Sep;161(9):1620-5.

PMID:
15337652
14.
15.

Novel antipsychotics: comparison of weight gain liabilities.

Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR.

J Clin Psychiatry. 1999 Jun;60(6):358-63.

PMID:
10401912
16.

Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.

Potvin S, Stip E, Roy JY.

Int Clin Psychopharmacol. 2003 May;18(3):121-32. Review.

PMID:
12702890
17.

Use of atypical antipsychotics in mood disorders.

Weizman R, Weizman A.

Curr Opin Investig Drugs. 2001 Jul;2(7):940-5. Review.

PMID:
11757795
18.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
19.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
20.

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

Glazer WM.

J Clin Psychiatry. 2000;61 Suppl 3:16-21. Review.

PMID:
10724129
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk